ESR1 and prostate cancer: Toth et al. reported that L3MBTL3 mutations were linked to a greater risk of developing multiple types of cancers, including colorectal, overall breast, estrogen receptor (ER)-negative breast, clear cell ovarian, and overall and aggressive prostate cancer risk [26,27].